The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard ...

Onsite in Chicago at ASCO 2025, web editor Nicole Raleigh sat down with Dr Danny Nguyen, medical oncologist and haematologist ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A European pharma trade organisation has said that a new strategy launched by the EU to bolster the region's standing in life ...

Like many industries, the pharmaceutical labour market has felt and will continue to feel the impacts of the COVID-19 pandemic moving into 2023 and beyond. A new operating model for pharma shifted ...

The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug in the ...

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested outside ...

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’. This ...

Mosawi founded Al Hayat to ensure that people in Iraq had access to life-saving medical products – after seeing first-hand the difficulties in bringing medicines to the country in the aftermath ...